About 107,165 results

ER+/HER2− BC: Age and Ki-67 index predict nodal response to NAC

Jun 23rd, 2022 - Key clinical point: In estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) neoadjuvant chemotherapy (NAC) should be considered to enable axillary conservation in patients aged <50 years with Ki67 ≥20%. Major finding: Both Ki67 ≥20% (adjusted odds ratio [aOR] 2.

Similar prognosis in pregnant vs. nonpregnant BC patients receiving chemotherapy

Jun 23rd, 2022 - Key clinical point: Patients with breast cancer (BC) treated with standard chemotherapy during pregnancy show comparable prognosis to young nonpregnant patients with BC, supporting chemotherapy initiation in pregnant women with BC as indicated. Major finding: Median follow-up was 66.

Male infertility and breast cancer: Is there a link?

Jun 23rd, 2022 - Key clinical point: Male-origin infertility was associated with an increased risk for breast cancer (BC) in men. Major finding: Risk for BC was significantly higher in men diagnosed with infertility (odds ratio [OR] 2.

Breast cancer: Epigallocatechin-3-gallate prevents dermatitis in patients receiving radiotherapy

Jun 23rd, 2022 - Key clinical point: Patients who received adjuvant radiotherapy for breast cancer (BC) experienced a significant reduction in radiation-induced dermatitis (RID) incidence and severity after the prophylactic use of epigallocatechin-3-gallate (EGCG) solution. Major finding: Incidence rates of grade ≥2 RID (50.

Metastatic BC and brain metastases: Etirinotecan pegol fails to improve survival in phase 3

Jun 23rd, 2022 - Key clinical point: Etirinotecan pegol failed to prolong survival compared with chemotherapy in patients with metastatic breast cancer (BC) and stable pretreated brain metastases (BM). Major finding: The median overall survival (hazard ratio [HR] 0.

Adjuvant radiotherapy less toxic in prone vs. supine position in BC patients with heavy breasts

Jun 23rd, 2022 - Key clinical point: Adjuvant breast intensity-modulated radiotherapy (IMRT) in the prone vs. supine position was less toxic in women with large breast size and early-stage breast cancer (BC) who underwent breast-conserving surgery (BCS).

Elacestrant prolongs survival in previously treated ER+/HER2− advanced BC

Jun 23rd, 2022 - Key clinical point: Elacestrant significantly improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine monotherapy in previously treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC) with a manageable safety. Major finding: Elacestrant vs.

Metformin disappoints in high-risk operable breast cancer

Jun 23rd, 2022 - Key clinical point: In patients with high-risk operable breast cancer (BC) and without diabetes, adding metformin to standard BC treatment did not improve the invasive disease-free survival (iDFS) rate, regardless of estrogen receptor/progesterone receptor (ER/PgR) status. Major finding: The incidence rates of iDFS events were similar between the metformin and placebo groups in patients with ER.

Advanced TNBC: Camrelizumab + apatinib and eribulin shows promise in heavily pretreated patients

Jun 23rd, 2022 - Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC). Major finding: The objective response rate (ORR), disease control rate, and median progression-free survival in the overall cohort were 37.

Primary BC: Weekly vs. every-3-week nab-paclitaxel improves pCR but with higher toxicity

Jun 23rd, 2022 - Key clinical point: Adding denosumab to anthracycline/taxane-based neoadjuvant chemotherapy (NACT) did not improve pathological complete response (pCR) rates, but a weekly vs. every-3-week nanoparticle albumin-bound ( nab)-paclitaxel regimen improved pCR rates in patients with early breast cancer (BC), although the toxicity was higher.

A Scrotal Rash Lasting Months in a Man With Genital Edema

Jun 23rd, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case you would like to suggest for a future Case Challenge, please conta...

IUD Injury Risk Rises Shortly After Women Give Birth

Jun 23rd, 2022 - Women for whom an intrauterine device (IUD) is inserted from 4 days to 6 weeks after giving birth, as well as those who are breastfeeding, are at higher risk of the contraceptive device puncturing their uterus, new research shows. Dr Susan Reed The risk of perforation was nearly seven times higher for patients who received an IUD within that window than for those with an IUD who'd never given b...

Dabrafenib-Trametinib Combo Approved for Range of Solid Tumors

Jun 23rd, 2022 - The US Food and Drug Administration has granted accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with the BRAF V600E mutation whose disease has progressed following prior treatment and who have no satisfactory alternative treatment options. The combination represents "the...

Large Benefit From Ovarian Function Suppression in Breast Cancer

Jun 23rd, 2022 - Eight-year follow-up of the ASTRRA trial confirmed and extended support for adding 2 years of ovarian function suppression with goserelin to tamoxifen, compared with tamoxifen alone. "Adding ovarian suppression to tamoxifen should be considered for this population of women," said senior author Hee Jeong Kim, MD, a breast cancer surgeon with the Asan Medical Center, Seoul, South Korea. Kim prese...

Breast duct treatment for early breast cancer eliminates all signs of disease in laboratory experiments

Jun 22nd, 2022 - Delivering a targeted immunotoxin into breast ducts via openings in the nipple wiped out all visible and invisible precancerous lesions in laboratory studies, led by researchers at the Johns Hopkins Kimmel Cancer Center, of very early stage breast cancers. A description of the work performed on mice, which the authors say provides a strong pre-clinical foundation for conducting feasibility and ...

Nordic lower-protein diet could hold key to instilling healthier eating habits in babies, new study finds

Jun 22nd, 2022 - (Copenhagen, 23 June 2022) Starting babies and toddlers on a lower protein Nordic-style diet with a greater focus on plant-based food may be the key to healthier eating habits, according to new research1 being presented today at the 54th Annual Meeting of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Babies fed taster portions of the new Nordic diet of...

ASCO 2022: An Abundance of Data for the Field of Melanoma

Jun 22nd, 2022 - Michael Postow, MD, offers an immediate reflection on compelling data surrounding adjuvant and neoadjuvant treatments for melanoma, as well as other items of clinical interest, presented at the ASCO 2022 conference. An update on the KEYNOTE-716 trial featured more news on the benefits of pembrolizumab in improving metastasis-free survival, and further results from the PRADO study underscored th...

Biden Nominates Arati Prabhakar as His Top Science Adviser

Jun 22nd, 2022 - WASHINGTON (Reuters) - U.S. President Joe Biden on Tuesday nominated Arati Prabhakar as the new White House science adviser, who would be the first woman of color and first immigrant to hold such a role if confirmed by the Senate. Prabhakar would head The Office of Science and Technology Policy at the White House. Her predecessor Eric Lander resigned from the post in February after violating th...

US Supreme Court Rejects Bayer Bid to Nix Roundup Weedkiller Suits

Jun 22nd, 2022 - WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Tuesday rejected Bayer AG's bid to dismiss legal claims by customers who contend its Roundup weedkiller causes cancer as the German company seeks to avoid potentially billions of dollars in damages. The justices turned away a Bayer appeal and left in place a lower court decision that upheld $25 million in damages awarded to California re...

Instead of Staging, 'Count the Number of Metastatic Lymph Nodes'

Jun 22nd, 2022 - In patients with solid tumors, the simple process of counting the number of metastatic lymph nodes (LN) offers the best predictor of mortality, a new analysis shows. It turned out to be better than more complicated processes involved in staging the lymph nodes, which involves examining the size of each node, its location, and how far the cancer has spread beyond the lymph node. These factors ar...